Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 – Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
3 Therapeutic Landscape 11
3.1 Heart Failure 11
3.1.1 Symptoms 11
3.1.2 Etiology 12
3.1.3 Pathophysiology 12
3.1.4 Co-morbidities and Complications 12
3.1.5 Diagnosis 13
3.1.6 Classification 14
3.1.7 Prognosis and Disease Staging 14
3.1.8 Treatment Options 15
3.2 Myocardial Infarction 18
3.2.1 Symptoms 18
3.2.2 Etiology 18
3.2.3 Pathophysiology 18
3.2.4 Co-morbidities and Complications 19
3.2.5 Diagnosis 19
3.2.6 Classification 20
3.2.7 Treatment Options 21
3.3 Acute Coronary Syndrome 22
3.3.1 Symptoms 22
3.3.2 Etiology 22
3.3.3 Pathophysiology 23
3.3.4 Diagnosis 23
3.3.5 Treatment Options 24
4 Marketed Products 27
4.1 Heart Failure 27
4.2 Myocardial Infarction 27
4.3 Acute Coronary Syndrome 27
4.4 Key Marketed Products 27
4.4.1 Arixtra 27
4.4.2 Brilinta 29
4.4.3 Crestor 30
4.4.4 Diovan and Diovan HCT/Co-Diovan 31
4.4.5 Atacand 31
4.4.6 Lipitor 32
4.4.7 Clopidogrel bisulfate 33
4.4.8 Angiomax 33
4.4.9 Lovenox 34
4.4.10 Norvasc 35
4.4.11 Coreg 35
4.4.12 Ivabradine 37
4.4.13 Toprol-XL 37
5 Pipeline Analysis 39
5.1 Heart Failure Pipeline 39
5.1.1 Overall Pipeline 39
5.1.2 Pipeline Analysis by Molecule Type 40
5.1.3 Pipeline Analysis by Mechanism of Action 41
5.2 Myocardial Infarction Pipeline 42
5.2.1 Overall Pipeline 42
5.2.2 Pipeline Analysis by Molecule Type 43
5.2.3 Pipeline Analysis by Mechanism of Action 44
5.3 Acute Coronary Syndrome Pipeline 45
5.3.1 Overall Pipeline 45
5.3.2 Pipeline Analysis by Molecule Type 46
5.3.3 Pipeline Analysis by Mechanism of Action 47
5.4 Promising Drug Candidates in the Pipeline 48
5.4.1 LCZ-696 48
5.4.2 Darapladib (SB-480848) 49
5.4.3 Neucardin 50
5.4.4 Cangrelor 51
5.4.5 Serelaxin (Novartis AG) 51
6 Cardiovascular Diseases Global Market to 2019, Market Forecast 52
6.1 Global Market 52
6.1.1 Treatment Usage Patterns 52
6.1.2 Annual Cost of Treatment 52
6.1.3 Market Size 52
6.2 US 54
6.2.1 Treatment Usage Patterns 54
6.2.2 Annual Cost of Treatment 54
6.2.3 Market Size 54
6.3 France 56
6.3.1 Treatment Usage Patterns 56
6.3.2 Annual Cost of Treatment 56
6.3.3 Market Size 56
6.4 Spain 58
6.4.1 Treatment Usage Patterns 58
6.4.2 Annual Cost of Treatment 58
6.4.3 Market Size 58
6.5 Germany 60
6.5.1 Treatment Usage Patterns 60
6.5.2 Annual Cost of Treatment 60
6.5.3 Market Size 60
6.6 Italy 62
6.6.1 Treatment Usage Patterns 62
6.6.2 Annual Cost of Treatment 62
6.6.3 Market Size 62
6.7 UK 64
6.7.1 Treatment Usage Patterns 64
6.7.2 Annual Cost of Treatment 64
6.7.3 Market Size 64
6.8 Japan 66
6.8.1 Treatment Usage Patterns 66
6.8.2 Annual Cost of Therapy 66
6.8.3 Market Size 66
6.9 Canada 68
6.9.1 Treatment Usage Patterns 68
6.9.2 Annual Cost of Treatment 68
6.9.3 Market Size 68
6.10 Drivers and Barriers for the Global Cardiovascular Diseases Market 70
6.10.1 Drivers 70
6.10.2 Barriers 70
7 Deals and Strategic Consolidations 71
7.1 Deals Analysis 71
7.2 Major Co-development Deals 73
7.2.1 Genzyme Enters into Agreement with Osiris Therapeutics 74
7.2.2 Les Laboratoires Servier Enters into Co-development Agreement with miRagen Therapeutics 74
7.2.3 Cytokinetics Signs Strategic Agreement with Amgen 74
7.2.4 Biogen Idec Inc. Enters into Agreement with Cardiokine Inc. 74
7.2.5 Bristol-Myers Squibb Enters into Co-Development Agreement with Ambrx Inc. 75
7.2.6 Angioblast Systems Inc. Enters into Co-Development Agreement with Abbott India Limited 75
7.3 Major Licensing Deals 76
7.3.1 Cephalon Inc. Enters into Licensing Agreement with Mesoblast Limited for Regenerative Medicine 77
7.3.2 The Medicines Company Enters into Licensing Agreement with Pfizer Inc. 77
7.3.3 BioLineRx, Ltd. Enters into Licensing Agreement With Ikaria Holdings, Inc. 77
7.3.4 KAI Pharmaceuticals, Inc. Enters into Licensing Agreement with Bristol-Myers Squibb 77
7.3.5 Theravance, Inc. Enters into Licensing Agreement with Merck & Co., Inc. for Cardiovascular Therapeutic Candidates 78
7.3.6 Novartis AG Enters into License Agreement with Portola Pharmaceuticals, Inc. 79
7.3.7 Salix Pharmaceuticals, Ltd. Enters into License Agreement with Merck & Co, Inc. 79
7.3.8 Amgen Enters into Licensing Agreement with Cytokinetics 79
8 Appendix 80
8.1 Market Definitions 80
8.2 Abbreviations 80
8.3 Sources 82
8.4 All Pipeline Drugs by Phase 84
8.4.1 Preclinical 84
8.4.2 Pre-registration 87
8.4.3 Phase I 88
8.4.4 Phase II 89
8.4.5 Phase III 91
8.4.6 Discontinued 92
8.4.7 Filing rejected/Withdrawn 93
8.5 Market Forecasts to 2019 93
8.5.1 Global 93
8.5.2 US 94
8.5.3 UK 95
8.5.4 France 96
8.5.5 Spain 97
8.5.6 Germany 98
8.5.7 Italy 99
8.5.8 Japan 100
8.5.9 Canada 101
8.6 Research Methodology 102
8.6.1 Coverage 102
8.6.2 Secondary Research 102
8.6.3 Primary Research 103
8.6.4 Therapeutic Landscape 103
8.6.5 Geographical Landscape 106
8.6.6 Pipeline Analysis 106
8.7 Expert Panel Validation 106
8.8 Contact Us 106
8.9 Disclaimer 106